Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of D-Fi for the Treatment of Wounds Due to DEB
Sponsor: Castle Creek Biosciences, LLC.
Summary
The purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.
Official title: Evaluation of Dabocemagene Autoficel (D-Fi; FCX-007; Genetically Modified Autologous Human Dermal Fibroblasts) for the Treatment of Wounds Due to Dystropic Epidermolysis Bullosa
Key Details
Gender
All
Age Range
2 Years - Any
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2025-03-27
Completion Date
2042-02
Last Updated
2026-03-13
Healthy Volunteers
No
Conditions
Interventions
D-Fi
D-Fi is composed of fibroblasts isolated from the subject's skin biopsies which are genetically corrected with the full length COL7A1 gene encoding for type VII collagen.
Locations (4)
Stanford University School of Medicine, Dermatology
Redwood City, California, United States
Mission Dermatology
Santa Margarita, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
University of Massachusetts
Worcester, Massachusetts, United States